Skip to Content

Join the 'Canagliflozin' group to help and get support from people like you.

Canagliflozin News

Blame Diabetes: Rates of 2 Nerve Conditions on the Rise

Posted 2 days 13 hours ago by Drugs.com

FRIDAY, July 21, 2017 – Two particular types of nerve damage (neuropathy) have been increasing as more and more people develop diabetes in the United States, an expert says. Autonomic and small fiber neuropathy were once rare conditions. Both occur when small blood vessels supplying the nerves are damaged by diabetes because they don't get enough oxygen and nutrients, said Dr. Divpreet Kaur, a neurologist at Penn State Health Milton S. Hershey Medical Center. Diabetes is one of the main causes of neuropathy, and about 30 million Americans currently have diabetes, Kaur said. More commonly, people with diabetes have nerve damage that causes numbness in the feet and toes. This is called peripheral neuropathy, according to the American Diabetes Association. Autonomic neuropathy affects involuntary bodily functions such as blood pressure, digestion, sexual function, urination, temperature ... Read more

Related support groups: Diabetes, Type 2, Metformin, Peripheral Neuropathy, Insulin, Lantus, Diabetes, Type 1, Diabetic Neuropathy, Glucophage, Glipizide, Novolog, Humalog, Insulin Resistance, Janumet, Diabetic Nerve Damage, Glyburide, Invokana, Lantus Solostar, Levemir, Actos, Glimepiride

Exercising Safely With Diabetes

Posted 17 days ago by Drugs.com

FRIDAY, July 7, 2017 – Exercise is a powerful tool for managing diabetes. Doing it safely can be a bit of a challenge, but the extra effort is worth it. Regular exercise has been shown to lower blood sugar levels. Working out uses sugar from your bloodstream to fuel your muscles. It also helps the insulin in your body to work better, according to the American Diabetes Association. Talk to your doctor about which activities are safe for you, what your blood sugar readings should be prior to working out, and what to look for when you test your blood sugar during as well as after exercise. You'll likely be told to always test your blood sugar before working out. If it's too high to exercise safely, wait until it's back under control. If it's too low, eat a small snack to help prevent hypoglycemia – dangerously low blood sugar, the U.S. Centers for Disease Control and Prevention ... Read more

Related support groups: Metformin, Insulin, Lantus, Glucophage, Glipizide, Novolog, Humalog, Insulin Resistance, Glyburide, Invokana, Lantus Solostar, Levemir, Actos, Glimepiride, Pre-Diabetes, Novolin R, Amaryl, Pioglitazone, Novolin N, Diabetes Mellitus

Can Folks With Type 2 Diabetes Forgo the Finger Stick?

Posted 11 Jun 2017 by Drugs.com

SATURDAY, June 10, 2017 – People with type 2 diabetes who aren't taking insulin don't necessarily need to check their blood sugar levels, a new study contends. Many of these patients use "finger prick" blood sugar monitors, but "testing blood sugar didn't have any impact on their blood sugar," said study author Dr. Laura Young, an assistant professor of medicine at the University of North Carolina. "The best way to control blood sugar is to take your medication the way your doctor asks you to and to take good care of yourself," she said. "The key is really taking your medications." Monitoring might be helpful when starting a new medication or changing doses, Young said. "But if someone is on insulin, they absolutely need to be tested regularly," she said. Insulin predisposes people to have blood sugar that's too low, a condition called hypoglycemia. Hypoglycemia can cause dizziness and ... Read more

Related support groups: Diabetes, Type 2, Metformin, Insulin, Glipizide, Glucophage, Insulin Resistance, Janumet, Glyburide, Invokana, Glimepiride, Amaryl, Diabetes Mellitus, Glucophage XR, Farxiga, GlipiZIDE XL, Jardiance, Glucotrol, ActoPlus Met, Glucotrol XL, Glumetza

Study Confirms Link Between SGLT2 inhibitors and Diabetic Ketoacidosis

Posted 7 Jun 2017 by Drugs.com

WEDNESDAY, June 7, 2017 – A new class of type 2 diabetes drugs called SGLT2 inhibitors could increase the risk of a rare, life-threatening complication of the disease called ketoacidosis, a new study warns. SGLT2 inhibitors include prescription medications such as canagliflozin, dapagliflozin and empagliflozin. Brand names are Invokana, Invokamet, Farxiga, Xigduo XR, Jardiance and Glyxambi. These drugs first became available in 2013, but in 2015 the U.S. Food and Drug Administration issued a warning about an increased risk for diabetic ketoacidosis when SGLT2 inhibitors are used. The condition typically occurs in people with type 1 diabetes. And while it is uncommon in people with type 2 diabetes, case reports have shown it can occur with type 2 disease, according to the study authors. Ketoacidosis can cause vomiting, abdominal pain, shortness of breath and swelling in the brain. Left ... Read more

Related support groups: Diabetes, Type 2, Diabetes, Type 1, Insulin Resistance, Invokana, Pre-Diabetes, Diabetes Mellitus, Farxiga, Jardiance, Diabetic Ketoacidosis (DKA), Glyxambi, Abnormal Glucose Tolerance, Canagliflozin, Xigduo XR, Qtern, Invokamet, Dapagliflozin, Synjardy, Dapagliflozin/metformin, Empagliflozin/metformin, Canagliflozin/metformin

Diabetes Drug Gets FDA Warning Due to Amputation Risk

Posted 17 May 2017 by Drugs.com

WEDNESDAY, May 17, 2017 – The type 2 diabetes prescription drug canagliflozin (brand names Invokana, Invokamet, Invokamet XR) appears to increase the risk of leg and foot amputations, the U.S. Food and Drug Administration now says. The FDA is requiring the medications to carry new warnings about the risk. The required warnings on the drug's labeling include the most serious and prominent boxed warning. The agency's decision is based on data from two large clinical trials showing that leg and foot amputations occurred about twice as often in patients taking canagliflozin as among those taking a placebo. Amputations of the toe and middle of the foot were the most common, but leg amputations below and above the knee also occurred. Some patients had more than one amputation, some had amputations involving both limbs, according to the FDA. Type 2 diabetes occurs when the body becomes ... Read more

Related support groups: Diabetes, Type 2, Diabetic Neuropathy, Insulin Resistance, Diabetic Nerve Damage, Invokana, Diabetes Mellitus, Canagliflozin, Invokamet, Canagliflozin/metformin, Invokamet XR

FDA Medwatch Alert: Canagliflozin (Invokana, Invokamet): Drug Safety Communication - Increased Risk of Leg and Foot Amputations

Posted 16 May 2017 by Drugs.com

ISSUE: Based on new data from two large clinical trials, the FDA has concluded that the type 2 diabetes medicine canagliflozin (Invokana, Invokamet, Invokamet XR) causes an increased risk of leg and foot amputations. FDA is requiring new warnings, including the most prominent Boxed Warning, to be added to the canagliflozin drug labels to describe this risk. Final results from two clinical trials – the CANVAS (Canagliflozin Cardiovascular Assessment Study) and CANVAS-R (A Study of the Effects of Canagliflozin on Renal Endpoints in Adult Participants With Type 2 Diabetes Mellitus) – showed that leg and foot amputations occurred about twice as often in patients treated with canagliflozin compared to patients treated with placebo, which is an inactive treatment. Amputations of the toe and middle of the foot were the most common; however, amputations involving the leg, below and above the kne ... Read more

Related support groups: Diabetes, Type 2, Invokana, Canagliflozin, Invokamet, Canagliflozin/metformin, Invokamet XR

Dealing With Diabetes Distress

Posted 16 Feb 2017 by Drugs.com

THURSDAY, Feb. 16, 2017 – People with diabetes have to think about their condition and make treatment decisions constantly – and all that extra work and worry can lead to psychological distress at times. "Diabetes distress" isn't the same as depression, however, diabetes experts note. It's a condition unique to the 24/7 demands that come with diabetes, particularly for people dependent on insulin. "The day you develop diabetes, it's like the universe just handed you a new full-time job that you have to do in addition to whatever else you're doing. It's a special job that has a big impact on the rest of your life. There's no pay and no vacation," said William Polonsky, president of the Behavioral Diabetes Institute in San Diego. Alicia McAuliffe-Fogarty, vice president of lifestyle management at the American Diabetes Association, put it this way: "Diabetes distress is the extra burden ... Read more

Related support groups: Diabetes, Type 2, Metformin, Insulin, Lantus, Diabetes, Type 1, Glucophage, Glipizide, Novolog, Humalog, Insulin Resistance, Janumet, Glyburide, Invokana, Lantus Solostar, Levemir, Actos, Glimepiride, Pre-Diabetes, Novolin R, Amaryl

Language Barrier May Keep Some Hispanics From Good Diabetes Care

Posted 23 Jan 2017 by Drugs.com

MONDAY, Jan. 23, 2017 – Hispanic-American type 2 diabetes patients who lack proficiency in English may end up with poorer care, a new study finds. Specifically, these patients were found to be much less likely than non-Hispanic patients to take newly prescribed diabetes medications as directed, the researchers said. The study "suggests that more needs to be done to improve adherence to newly prescribed medications among Latino patients at all levels of English proficiency," wrote a team led by Dr. Alicia Fernandez, of the University of California, San Francisco. A diabetes specialist who reviewed the study wasn't surprised by the results. The research "further validates what many clinicians already know: Patients who do not understand English tend to do worse with management of chronic disease," said Dr. Maria Pena. She is an endocrinologist who directs the Center for Weight Management ... Read more

Related support groups: Diabetes, Type 2, Metformin, Insulin, Lantus, Diabetes, Type 1, Glucophage, Glipizide, Novolog, Humalog, Insulin Resistance, Janumet, Glyburide, Invokana, Lantus Solostar, Levemir, Actos, Glimepiride, Pre-Diabetes, Novolin R, Amaryl

Metformin Still Best Choice for First Type 2 Diabetes Treatment

Posted 3 Jan 2017 by Drugs.com

MONDAY, Jan. 2, 2017 – Newly updated guidelines reaffirm that metformin is the first-line drug for people with type 2 diabetes, and that several other medications – including newer ones – can be added if needed. The recommendations come from the American College of Physicians (ACP). The American Academy of Family Physicians endorsed the new guidelines. The ACP updated the guidelines because of new research into diabetes drugs, and the U.S. Food and Drug Administration approval of new diabetes drugs. "Metformin, unless contraindicated, is an effective treatment strategy because it has better effectiveness, is associated with fewer adverse effects, and is cheaper than most other oral medications," ACP president Dr. Nitin Damle said in a college news release. "The escalating rates of obesity in the U.S. are increasing the incidence and prevalence of diabetes substantially. Metformin has ... Read more

Related support groups: Diabetes, Type 2, Metformin, Januvia, Glipizide, Glucophage, Janumet, Glyburide, Invokana, Actos, Glimepiride, Pre-Diabetes, Amaryl, Pioglitazone, Tradjenta, Avandia, Glucophage XR, Farxiga, GlipiZIDE XL, Jardiance, Glucotrol

Have Type 2 Diabetes? Try Walking After Eating

Posted 18 Oct 2016 by Drugs.com

TUESDAY, Oct. 18, 2016 – For people with type 2 diabetes, a short walk after eating may help lower blood sugar levels more than exercising at other times of the day, a new study shows. A measurement of blood sugar called postprandial glycemia, which has been linked with heart disease risk, averaged 12 percent lower when study participants took a walk after eating, compared with those who exercised at other times. The largest drop in postprandial glycemia, 22 percent, was achieved by walking after dinner, the study authors found. "If you have type 2 diabetes, there is a guideline to be active for at least 150 minutes a week," said study author Andrew Reynolds, a researcher at the University of Otago, in New Zealand. But, he added, "the benefits we observed due to physical activity after meals suggest that current guidelines should be amended to specify after-meal activity, particularly ... Read more

Related support groups: Diabetes, Type 2, Heart Disease, Glipizide, Insulin Resistance, Glyburide, Invokana, Actos, Glimepiride, Pre-Diabetes, Amaryl, Pioglitazone, Diabetes Mellitus, Avandia, Farxiga, GlipiZIDE XL, Glucotrol, Jardiance, Acarbose, Glucotrol XL, Ischemic Heart Disease

FDA Approves Invokamet XR (Canagliflozin/Metformin Hydrochloride Extended-Release) for the Treatment of Adults with Type 2 Diabetes

Posted 22 Sep 2016 by Drugs.com

RARITAN, N.J., September 21, 2016 – Janssen Pharmaceuticals, Inc. (Janssen) announced today the U.S. Food and Drug Administration (FDA) has approved Invokamet XR - a once-daily, fixed-dose combination therapy of canagliflozin and metformin hydrochloride extended-release (XR)—for first-line use as an adjunct to diet and exercise to improve blood glucose control in adults with type 2 diabetes when treatment with the two medications is appropriate.[1] Invokamet XR combines Invokana (canagliflozin), the most prescribed sodium glucose co-transporter 2 (SGLT2) inhibitor, with more than 9 million U.S. prescriptions since launch,[2] and an XR formulation of metformin. Metformin is commonly prescribed as an initial therapy for the treatment of type 2 diabetes. “Invokamet XR offers the convenience of once-daily dosing and provides physicians needed flexibility for tailoring treatment to the needs ... Read more

Related support groups: Diabetes, Type 2, Metformin, Invokana, Canagliflozin, Invokamet, Canagliflozin/metformin

Intensive Type 2 Diabetes Treatment Can Extend Survival: Study

Posted 8 Sep 2016 by Drugs.com

WEDNESDAY, Sept. 7, 2016 – Intensive management of type 2 diabetes can make a difference in how long and how well you live, even if you don't start until middle age, researchers report. People who were already at risk of type 2 diabetes complications were randomly selected to continue with their normal treatment or to be placed in an aggressive and multipronged treatment group. Two decades after the study began, the researchers found that people in the aggressive treatment group lived almost eight years longer. Not only that, they lived better – their risk of heart disease, kidney disease and blindness all dropped. The only complication that didn't seem to improve was nerve damage caused by diabetes. "Early, intensified intervention in type 2 diabetes patients with microalbuminuria with both target-driven pharmacological (medication) and behavioral actions increased life span. And, ... Read more

Related support groups: Diabetes, Type 2, Metformin, Insulin, Victoza, Lantus, Januvia, Glipizide, Glucophage, Saxenda, Novolog, Humalog, Janumet, Byetta, Glyburide, Bydureon, Invokana, Lantus Solostar, Levemir, Trulicity, Actos

FDA Medwatch Alert: Canagliflozin (Invokana, Invokamet) and Dapagliflozin (Farxiga, Xigduo XR): Drug Safety Communication - Strengthened Kidney Warnings

Posted 15 Jun 2016 by Drugs.com

ISSUE: FDA has strengthened the existing warning about the risk of acute kidney injury for the type 2 diabetes medicines canagliflozin (Invokana, Invokamet) and dapagliflozin (Farxiga, Xigduo XR).  Based on recent reports, we have revised the warnings in the drug labels to include information about acute kidney injury and added recommendations to minimize this risk. BACKGROUND: Canagliflozin and dapagliflozin are prescription medicines used with diet and exercise to help lower blood sugar in adults with type 2 diabetes.  They belong to a class of drugs called sodium-glucose cotransporter-2 (SGLT2) inhibitors.  Canagliflozin and dapagliflozin lower blood sugar by causing the kidneys to remove sugar from the body through the urine. From March 2013, when canagliflozin was approved, to October 2015, FDA received reports of 101 confirmable cases* of acute kidney injury, some requiring ho ... Read more

Related support groups: Diabetes, Type 2, Invokana, Farxiga, Canagliflozin, Xigduo XR, Dapagliflozin, Invokamet, Canagliflozin/metformin, Dapagliflozin/metformin

Intensive Blood Sugar Control May Be Too Much for Some With Type 2 Diabetes

Posted 6 Jun 2016 by Drugs.com

MONDAY, June 6, 2016 – Intensive treatment of blood sugar levels in some people with type 2 diabetes may cause serious complications, new research suggests. "In this study, we found that, particularly among older patients and patients with serious chronic conditions, intensive treatment nearly doubled the risk of severe hypoglycemia requiring medical attention, including hospitalization," said lead author Dr. Rozalina McCoy. She is an endocrinologist at the Mayo Clinic in Rochester, Minn. Hypoglycemia (low blood sugar) is a serious potential complication of diabetes treatment. The researchers said it can worsen quality of life and has been linked with cardiovascular events, dementia and death. The researchers reviewed information from more than 31,500 American adults. All had stable and controlled type 2 diabetes. None was taking insulin. None had a prior history of severe ... Read more

Related support groups: Diabetes, Type 2, Metformin, Insulin, Lantus, Dementia, Glucophage, Glipizide, Novolog, Humalog, Hypoglycemia, Janumet, Glyburide, Invokana, Lantus Solostar, Levemir, Actos, Glimepiride, Novolin R, Amaryl, Novolin N

FDA Expands Indication of Invokamet (canagliflozin/metformin HCl) to Include First-Line Treatment of Type 2 Diabetes

Posted 31 May 2016 by Drugs.com

RARITAN, N.J., May 24, 2016 – Janssen Pharmaceuticals, Inc. (Janssen), today announced the U.S. Food and Drug Administration (FDA) has approved Invokamet, a fixed-dose combination therapy of INVOKANA® (canagliflozin) and metformin hydrochloride, for first-line treatment of adults with type 2 diabetes. With this new approval, Invokamet may now be prescribed in adults with type 2 diabetes who are not already being treated with canagliflozin or metformin and may benefit from dual therapy.[1] Invokamet, the first combination of a sodium glucose co–transporter 2 (SGLT2) inhibitor and metformin available in the United States, was previously approved by the FDA in August 2014 as an adjunct to diet and exercise to improve blood glucose control in adults with type 2 diabetes not adequately controlled by either canagliflozin or metformin, or who are already being treated with both medications sep ... Read more

Related support groups: Diabetes, Type 2, Metformin, Canagliflozin, Invokamet, Canagliflozin/metformin

Page 1 2 Next

Ask a Question

Further Information

Related Condition Support Groups

Diabetes, Type 2

Related Drug Support Groups

Invokana

Canagliflozin Patient Information at Drugs.com